- Yuexin is director at Life Sciences team. He is involved in portfolio companies Amolyt (acquired by AZ), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), JenaValve (acquired by Edwards), Mineralys (MLYS), Tubulis, Evommune, Artios, and TargED.
- Before joining Andera, Yuexin was at 3H Health Investment Management based in Hong Kong and Shanghai. He made the investments in InnoCare (HK.9969, SH.688428), KeyMed (HK.2162), CanSino (HK.6185), RareStone, EdiGen, Imperative Care, and HeMo Bioengineering.
- Prior to VC life, Yuexin has worked on life cycle management of Remicade and Keytruda at MSD. Before that, he has worked at bioMérieux in the corporate venture Mérieux Développement and the affiliate company Biotheranostics (later acquired by Hologic) in the US.
- Yuexin has a pharmacy degree from SJTU and a business degree from HEC Paris. He speaks Chinese, English and French.
Investments of Yuexin
Mineralys Therapeutics
Clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension
Tubulis
Antibody drug conjugates for the treatment of cancer
Targed
Biotechnology company focused on developing improved treatments for thrombotic diseases
The team andera Life Sciences
Raphaël Wisniewski
Partner
Olivier Litzka
Partner
Sofia Ioannidou
Partner
Jan Van den Bossche
Partner
Aneta Sottil
Partner
Mathieu Piéronne
Director
Yuexin Yu
Director
Natali Romero Barrios
Senior Investment Manager
Yanis Feraoun
Investment Manager
Elyes Chouaieb
Investment Director
Loan Hoang-Sayag
Venture Partner
Florian Gerard-Mercier
Investment Director
Thierry Hercend
Venture Partner
Armelle Okoye
Middle Office
Hans J. Moebius
Venture Advisor
Raymond W. Cohen
Venture Advisor
Vanessa Bonvalot
Executive Assistant